Current Opinion in Oncology最新文献_第9页

State of the art and upcoming trends in claudin-directed therapies in gastrointestinal malignancies. 胃肠道恶性肿瘤的克劳丁定向疗法的最新进展和未来趋势。

IF 3.4 4区医学

Current Opinion in Oncology Pub Date : 2024-07-01 Epub Date: 2024-04-23 DOI: 10.1097/CCO.0000000000001041

Jane E Rogers, Jaffer A Ajani

{"title":"State of the art and upcoming trends in claudin-directed therapies in gastrointestinal malignancies.","authors":"Jane E Rogers, Jaffer A Ajani","doi":"10.1097/CCO.0000000000001041","DOIUrl":"10.1097/CCO.0000000000001041","url":null,"abstract":"Purpose of review: Claudins, components of tight cell junctions in epithelial and endothelial cells, have emerged as a therapeutic target in gastrointestinal (GI) malignancies, particularly claudin 18.2 (CLDN18.2).Recent findings: Zolbetuximab, a chimeric anti-CLDN18.2 monoclonal antibody (mAb), is currently under FDA review and may emerge as the first claudin targeted therapy approved. Phase 3 trials show that zolbetuximab in combination with front-line fluoropyrimidine plus oxaliplatin improves survival in advanced CLDN18.2 positive (≥75% of tumor cells) gastric adenocarcinoma (GAC) patients. Many other therapies (mAbs; CART; bispecific; ADCs) are under investigation.Summary: CLDN18.2 will be an important target in GAC. Early understanding of how to target CLDN18.2 based on the level of expression (high, moderate, low) will be the key to success in this area. Studying these as separate entities should be considered. Resistance patterns, loss of CLDN18.2 expression, role in the refractory setting, and if any role in localized disease are questions that remain. Other targets for claudin that target claudin six and four are under investigation. Their role in GI malignancies will soon be further clarified.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"308-312"},"PeriodicalIF":3.4,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140897372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

State of the art and upcoming trends in HER2-directed therapies in gastrointestinal malignancies. 胃肠道恶性肿瘤中 HER2 靶向疗法的最新进展和未来趋势。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2024-07-01 Epub Date: 2024-05-01 DOI: 10.1097/CCO.0000000000001043

Jaeyop Lee, Geoffrey Ku

{"title":"State of the art and upcoming trends in HER2-directed therapies in gastrointestinal malignancies.","authors":"Jaeyop Lee, Geoffrey Ku","doi":"10.1097/CCO.0000000000001043","DOIUrl":"10.1097/CCO.0000000000001043","url":null,"abstract":"Purpose of review: This review critically evaluates the evolution and current status of human epidermal growth factor receptor 2 (HER2)-directed therapies in upper gastrointestinal (GI) malignancies, a timely and relevant inquiry given the dynamic shifts in therapeutic strategies over the past decade. Initial enthusiasm following the Trastuzumab for Gastric Cancer (ToGA) study's demonstration of trastuzumab's efficacy, however, encountered hurdles due to subsequent trials showing limited progress, underscoring the necessity for a reevaluation of therapeutic approaches and the exploration of novel agents.Recent findings: The review highlights significant breakthroughs in the form of immune checkpoint inhibitors and innovative therapeutic technologies, which have redefined treatment paradigms and shown promising efficacy in HER2-positive cases. Emerging treatments such as trastuzumab deruxtecan (T-DXd), zanidatamab and evorpacept further illustrate the ongoing efforts to leverage unique mechanisms of action for improved HER2-positive antitumor activity.Summary: The advancements in HER2-directed therapies underscore a pivotal era in the management of upper GI malignancies. These developments not only reflect the profound impact of integrating novel therapeutic combinations but also highlight the critical role of ongoing research in overcoming resistance mechanisms and tailoring treatment to individual disease profiles.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"326-331"},"PeriodicalIF":2.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11611523/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140897401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in testing for human papillomavirus -mediated head and neck cancer. 人类乳头瘤病毒介导的头颈癌检测进展。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2024-05-01 Epub Date: 2024-03-19 DOI: 10.1097/CCO.0000000000001029

Hisham Mehanna, Laia Alemany, Christian von Buchwald

{"title":"Advances in testing for human papillomavirus -mediated head and neck cancer.","authors":"Hisham Mehanna, Laia Alemany, Christian von Buchwald","doi":"10.1097/CCO.0000000000001029","DOIUrl":"10.1097/CCO.0000000000001029","url":null,"abstract":"Purpose of review: New evidence has recently emerged regarding the utility and benefits of dual p16 INKa (p16) and Human papillomavirus (HPV) status testing when determining the diagnosis and prognosis of patients with oropharyngeal cancer.Recent findings: HPV RNA polymerase chain reaction (PCR) is the most accurate diagnostic test. The other assays (HPV DNA PCR, HPV DNA/RNA in-situ hybridization (ISH) and p16) applied to formalin fixed tumour tissue have varying but high sensitivities and specificities. Dual p16 and HPV testing identifies discordant (p16+/HPV- or p16-/HPV+) results in 9.2% of cases, who have significantly poorer prognoses than p16+/HPV+, particularly in smokers. The proportion of discordant cases varies by region, and appears to be highest in regions with lowest attributable (p16+/HPV+) fractions. Dual testing improves prognostication for oropharyngeal cancer cases by identifying discordant cases and improving the prognostic power of the Tumour Node Metastasis (TNM) classification, especially in regions with high discordant rates.Summary: Dual testing is essential when considering patients for clinical trials of treatment de-escalation, and may be important when counselling patients on prognosis, especially in regions with high discordant rates and in smokers.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"143-146"},"PeriodicalIF":2.8,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10990024/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140173997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular and nutritional markers in head and neck cancer. 头颈癌的分子和营养标记。

IF 3.4 4区医学

Current Opinion in Oncology Pub Date : 2024-05-01 Epub Date: 2024-02-29 DOI: 10.1097/CCO.0000000000001034

Gerard Milano, Jocelyn Gal, René-Jean Bensadoun

{"title":"Molecular and nutritional markers in head and neck cancer.","authors":"Gerard Milano, Jocelyn Gal, René-Jean Bensadoun","doi":"10.1097/CCO.0000000000001034","DOIUrl":"10.1097/CCO.0000000000001034","url":null,"abstract":"Purpose of review: There is still a need of biomarkers in the induction and neoadjuvant settings for squamous cell carcinoma of the head and neck (SCCHN). The objective of this concise review article is to give an overview on both predictive and prognostic biomarkers potentially useful for the management of SCCHN.Recent findings: Human papilloma virus (HPV) positivity translated by the presence of the protein indicator p16 is synonymous of favorable prognosis SCCHN. However, there is some disparity for disease evolution among p16 positive SCCHN. A lack of correlation between immunohistochemistry (IHC) and precise quantification of active epidermal growth factor receptors (EGFRs) may explain the absence of link between EGFR expression performed by IHC and response to EGFR targeting therapies reported in SCCHN. Circulating tumor cells (CTCs) have the property to share the main somatic mutations and genetic rearrangements with the primary tumors. A particular potential interest lies on the possibility to predict patient outcome based on a single-CTC analysis.Summary: This short review indicates that key biological marker reflecting disease outcome is not yet emerging for a clinical use in SCCHN. Hopes can be put into the so-called liquid biopsies incorporating circulating tumor cells and circulating tumor DNA.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"123-127"},"PeriodicalIF":3.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140027621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stereotactic ablative radiation therapy in metastatic prostate cancer. 转移性前列腺癌的立体定向消融放射治疗。

IF 3.4 4区医学

Current Opinion in Oncology Pub Date : 2024-05-01 Epub Date: 2024-02-15 DOI: 10.1097/CCO.0000000000001025

Soha Bazyar, Heather Mannuel, Phuoc T Tran

{"title":"Stereotactic ablative radiation therapy in metastatic prostate cancer.","authors":"Soha Bazyar, Heather Mannuel, Phuoc T Tran","doi":"10.1097/CCO.0000000000001025","DOIUrl":"10.1097/CCO.0000000000001025","url":null,"abstract":"Purpose of review: The evolving role of stereotactic ablative radiation therapy (SABR) as metastasis-directed therapy (MDT) for oligometastatic prostate cancer (omPCa) will be discussed.Recent findings: Oligometastatic disease (OMD) is an intermediate state between localized and wide-spread malignant disease. OMD has recently been spotlighted given the increasing demonstration of clinical benefit from local therapies despite presence of metastatic disease and allure of the curative potential of MDT in select cases. Among the different forms of MDT, SABR has rapidly become a widely adopted treatment modality. Significant efforts in this space have focused on omPCa, owing to its relatively indolent biology, presence of a sensitive and specific serum biomarker and recent advances in molecular imaging. While most studies have evaluated the role of SABR MDT in hormone sensitive omPCa, new emerging clinical data also suggests benefits of SABR MDT for even castration-resistant disease.Summary: Treating omPCa with SABR MDT appears to generate an efficacy signal with minimal morbidity across both hormone-sensitive and castration-resistant disease. However, additional definitive omPCa trial data are needed. Future research efforts should investigate biomarkers for this heterogeneous disease space and the role of SABR MDT in combination with systemic agents to improve upon standard of care treatments.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"180-185"},"PeriodicalIF":3.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10990008/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139740673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Highlighting recent progress in the treatment of men with advanced prostate cancer. 重点介绍治疗晚期前列腺癌患者的最新进展。

IF 3.4 4区医学

Current Opinion in Oncology Pub Date : 2024-03-13 DOI: 10.1097/cco.0000000000001035

Theodore Gourdin

引用次数: 0

Head and neck cancer patients treated with concomitant chemoradiotherapy involving the oral cavity and oropharynx: is another choice possible than prophylactic gastrostomy? 头颈部癌症患者同时接受涉及口腔和口咽的放化疗：除了预防性胃造口术，还有其他选择吗？

IF 3.4 4区医学

Current Opinion in Oncology Pub Date : 2024-03-08 DOI: 10.1097/cco.0000000000001031

Pierre Senesse, Jeanne Briant, Pierre Boisselier, René-Jean Bensadoun, Marie Vinches, Kerstin Faravel

引用次数: 0

Organ preservation in muscle-invasive urothelial bladder cancer. 肌层浸润性尿路膀胱癌的器官保留。

IF 3.4 4区医学

Current Opinion in Oncology Pub Date : 2024-03-08 DOI: 10.1097/cco.0000000000001038

Scot A Niglio, Juhi M Purswani, Peter B Schiff, Jonathan W Lischalk, William C Huang, Katie S Murray, Andrea B Apolo

引用次数: 0

Tripartite motif family - its role in tumor progression and therapy resistance: a review. 三方图案家族--在肿瘤进展和耐药性中的作用：综述。

IF 3.4 4区医学

Current Opinion in Oncology Pub Date : 2024-03-01 Epub Date: 2024-01-16 DOI: 10.1097/CCO.0000000000001021

Yongqi Zhang, Ying Guan, Shuxiang Wang, Chunyan Guan, Xiaoli Liu

引用次数: 0

Single agent vs combination immunotherapy in advanced melanoma: a review of the evidence. 晚期黑色素瘤的单药与联合免疫疗法：证据综述。

IF 3.4 4区医学

Current Opinion in Oncology Pub Date : 2024-03-01 Epub Date: 2024-01-02 DOI: 10.1097/CCO.0000000000001014

Nada Benhima, Rhizlane Belbaraka, Mireille D Langouo Fontsa

{"title":"Single agent vs combination immunotherapy in advanced melanoma: a review of the evidence.","authors":"Nada Benhima, Rhizlane Belbaraka, Mireille D Langouo Fontsa","doi":"10.1097/CCO.0000000000001014","DOIUrl":"10.1097/CCO.0000000000001014","url":null,"abstract":"Purpose of review: The aim of this review is to outline the current landscape of advanced melanoma treatment options, provide insights on selecting combination therapies within different clinical scenarios, capture clinical relevance of anti-programmed cell death protein 1 (PD-1) monotherapy, and explore the unmet needs with immune check-point inhibitors (ICI) in advanced melanoma.Recent findings: ICI based treatment consisted of single agent ICI or dual combination ICI-ICI is the standard of care of front-line treatment of metastatic or unresectable melanoma. PD-1 inhibitors (Pembrolizumab and Nivolumab) improved progression free survival (PFS) and overall survival (OS) compared to chemotherapy and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) inhibitors (Ipilimumab and Tremelimumab). The dual ICI combination (Nivolumab and Ipilimumab) provided profound and durable responses better than monotherapy, and the longest overall survival ever achieved in advanced disease, including in patients with murine sarcoma viral oncogene homolog B (BRAF)-mutated disease, but at the cost of a high risk of severe toxicity. The new dual blockage of LAG-3 and PD-1 (Nivolumab-Relatlimab) emerges as a valid option with promising efficacy outcomes and a favourable toxicity profile. Mature survival data is still needed to capture the real benefit.Summary: These new plethora of options pose new challenges not only for optimal treatment sequencing strategies but especially for management of adverse effects, endorsing the need to integrate a holistic and personalized approach for patient care.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"69-73"},"PeriodicalIF":3.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139402232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0